Indo Borax Q1FY27 Results: Net profit rises 59% YoY to ₹16.25 crore
- Consolidated net profit rose 59.31% YoY to ₹16.25 crore for Q1FY27
- Revenue grew 31.34% to ₹70.36 crore, up from ₹53.57 crore in Q1FY26
- EBITDA increased 62.16% to ₹19.80 crore with margins at 28.14%
- Board approved acquisition of 64.26% stake in Kronox Lab Sciences for ₹246.12 crore

*this image is generated using AI for illustrative purposes only.
Indo Borax & Chemicals Ltd indo borax & chemicals reported a 59.31% year-on-year increase in consolidated net profit to ₹16.25 crore for the quarter ended June 30, 2026. The specialty chemicals manufacturer also saw its revenue jump 31.34% to ₹70.36 crore, supported by improved capacity utilization and better realizations.
The company’s earnings per share (EPS) stood at ₹5.07 for the period, up from ₹3.20 in Q1FY26. Management attributed the strong performance to steady domestic demand and operational efficiencies across its Pithampur facility in Madhya Pradesh.
Financial Performance
Consolidated operating revenue expanded significantly compared to the previous quarter and fiscal year period. EBITDA rose sharply, reflecting improved margin dynamics.
| Metric | Q1FY26 | Q4FY26 | Q1FY27 | YoY Change |
|---|---|---|---|---|
| Revenue (₹ crore) | 53.57 | 63.01 | 70.36 | +31.34% |
| EBITDA (₹ crore) | 12.21 | 12.82 | 19.80 | +62.16% |
| Net Profit (₹ crore) | 10.20 | 14.53 | 16.25 | +59.31% |
For the full FY26, the company logged a revenue of ₹215.45 crore, a 22.9% increase over FY25’s ₹175.26 crore. Full-year net profit grew 18.3% to ₹50.27 crore, with an EPS of ₹15.67. Despite the revenue growth, full-year EBITDA contracted slightly to ₹44.16 crore from ₹45.89 crore in FY25, maintaining a healthy margin of 20.5%.
What the Numbers Show
The divergence between quarterly and annual profitability metrics highlights significant improvement in recent months. While full-year FY26 EBITDA declined marginally despite substantial revenue growth, Q1FY27 EBITDA surged 62.16% to ₹19.80 crore. This suggests that the operational efficiencies and better realizations cited by management have had a pronounced impact in the current quarter, reversing the slight margin pressure seen during the broader fiscal year.
Strategic Developments
Post-quarter, the Board of Directors approved two major strategic moves:
- Amalgamation: The company will amalgamate its wholly owned subsidiary, Indoborax Infrastructure Private Limited, to streamline governance and enhance resource utilization.
- Acquisition: Indo Borax approved the acquisition of 64.26% equity shares of Kronox Lab Sciences for an aggregate consideration of ₹246.12 crore. The deal includes an open offer for up to 25.79% additional stake. Kronox, which reported FY26 revenue of ₹101 crore and PAT of ~₹28 crore, brings 185+ specialty chemical products and export presence to the group.
Managing Director Suresh Kalra stated that the acquisition aims to leverage Kronox’s experience to fortify margins through synergies. The company remains debt-free and continues to focus on expanding its boric acid and Disodium Octaborate Tetrahydrate (DOT) portfolio, targeting incremental domestic demand in steel, ceramics, and agriculture sectors.
Historical Stock Returns for Indo Borax & Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.49% | +2.73% | +37.65% | +111.19% | +115.69% | 0.0% |
How will the integration of Kronox Lab Sciences impact Indo Borax's debt profile, given the ₹246.12 crore acquisition cost?
What specific operational synergies are expected to materialize between Indo Borax and Kronox to justify the premium paid for the acquisition?
Will the amalgamation of Indoborax Infrastructure Private Limited result in immediate tax benefits or streamlined regulatory compliance for the group?


































